erlotinib hydrochloride has been researched along with Glioma in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (37.50) | 29.6817 |
| 2010's | 24 (60.00) | 24.3611 |
| 2020's | 1 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, S; Elmquist, WF; Manchanda, P; Ohlfest, JR; Vogelbaum, MA | 1 |
| Cao, D; Hu, B; Hwang, I; Jang, JY; Li, JY; Oh, H; Paik, J; Wang, Q; Wu, L; Yao, J; Yao, Y; Ying, H; Zheng, H | 1 |
| Broniscer, A; Hua, CH; Hwang, SN; Knapp, BJ; Lucas, JT; Merchant, TE; Patay, Z; Uh, J | 1 |
| Broniscer, A; Cooper, DA; Hwang, S; Li, X; Li, Y; Lucas, JT; Merchant, TE; Orr, B; Tinkle, C | 1 |
| Beccaria, K; Blauwblomme, T; Boddaert, N; Bolle, S; Brunelle, F; Calmon, R; Castel, D; Dhermain, F; Dufour, C; Grevent, D; Grill, J; Puget, S; Sainte-Rose, C; Saitovitch, A; Varlet, P; Zilbovicius, M | 1 |
| Agar, JN; Agar, NY; Alberta, J; Davis, E; Easterling, ML; Ebling, MC; Ide, JL; Kellersberger, KA; Kesari, S; Liu, X; Marchionni, MA; Norton, I; Santagata, S; Sauvageot, CM; Stiles, CD; Stuart, DD; Wang, LY | 1 |
| Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Drappatz, J; Gilbert, MR; Groves, MD; Kuhn, JG; Lamborn, KR; Lieberman, FS; Ligon, AH; Ligon, KL; Mehta, MP; Norden, AD; Prados, MD; Robins, HI; Santagata, S; Wen, PY; Wright, JJ; Yung, WK | 1 |
| Canoll, P; Chen, S; Guo, B; Horner, JW; Klingler, S; Paik, JH; Vaseva, AV; Wang, YA; Yan, H; Yao, J; Ying, H; Zhang, L; Zheng, H | 1 |
| Ali, SM; Blumenthal, DT; Bokstein, F; Dvir, A; Limon, D; Lior, T; Lokiec, A; Lossos, A; Ram, Z; Ross, JS; Soussan-Gutman, L; Tzuk-Shina, T; Yair, R; Yust-Katz, S | 1 |
| Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Karpel-Massler, S; Kast, RE; Nonnenmacher, L; Siegelin, MD; Westhoff, MA; Wirtz, CR | 1 |
| Bajetto, A; Barbieri, F; Capra, MC; Corte, G; Daga, A; Favoni, RE; Florio, T; Gatti, M; Griffero, F; Lo Casto, M; Marubbi, D; Melotti, A; Pattarozzi, A; Porcile, C; Spaziante, R; Zona, G | 1 |
| Baker, SJ; Broniscer, A; Ellison, DW; Endersby, R; Gajjar, A; Kocak, M; Laningham, FH; Merchant, TE; Morris, EB; Schaiquevich, P; Stewart, CF | 1 |
| Broniscer, A; Christiansen, SR; Panetta, JC; Stewart, CF | 1 |
| D'Elia, A; Formichella, AI; Frati, A; Salvati, M | 1 |
| Al-Sarraj, S; Bax, DA; Ellison, DW; Gaspar, N; Hargrave, D; Jones, C; Little, SE; Marshall, L; Pearson, AD; Perryman, L; Regairaz, M; Reis, RM; Reis-Filho, JS; Sharp, SY; Stávale, JN; Vassal, G; Viana-Pereira, M; Vuononvirta, R; Workman, P | 1 |
| Abrey, LE; Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Abrey, LE; Aldape, KA; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Boockvar, JA; Edgar, MA; Karampelas, I; Luther, N; Souliopoulos, EP; Souweidane, MM | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Hamilton, M; Herndon, JE; Marcello, J; Mathe, A; McLendon, RE; Norfleet, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Aerts, I; Andreiuolo, F; Chatelut, E; Frappaz, D; Gentet, JC; Geoerger, B; Hargrave, D; Jaspan, T; Le Deley, MC; Leblond, P; Méresse, V; Morland, B; Ndiaye, A; Paoletti, X; Riccardi, R; Saint-Rose, C; Thomas, F; Varlet, P; Vassal, G | 1 |
| Bota, DA; Gong, X; Linskey, ME; Schwartz, PH | 1 |
| Halatsch, ME; Karpel-Massler, G; Wirtz, CR | 1 |
| Amberger-Murphy, V; Clarke, C; Clynes, M; Doolan, P; Farrell, M; Howley, R; Kinsella, P; Madden, SF | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; McLendon, RE; McSherry, F; Peters, KB; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Threatt, S; Vredenburgh, JJ; Zhang, S | 1 |
| Constantini, S; Kane, R; MacDonald, TJ; McCowage, G; Packer, RJ; Rood, B; Yalon, M | 1 |
| Lemmon, MA; Park, JH | 1 |
| Barkovich, KJ; Blair, JA; Fan, QW; Garske, AL; Hariono, S; Nicolaides, T; Shokat, KM; Weiss, WA; Zhang, J | 1 |
| Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S | 1 |
| Codacci-Pisanelli, G; Della Rocca, C; Frati, L; Gulino, A; Lo Russo, G; Miele, E; Miscusi, M; Papa, A; Petrozza, V; Spinelli, GP; Tomao, S | 1 |
| Cloughesy, T; Green, RM; Lai, A; Nghiemphu, PL; Reardon, DA | 1 |
| Campos-Martín, Y; García-Claver, A; Lorente, M; Meléndez, B; Mollejo, M; Mur, P; Velasco, G | 1 |
| Bryant, JA; Charles, AC; Cloughesy, TF; Finn, RS; Slamon, DJ | 1 |
| Cappuzzo, F | 1 |
| Arvold, ND; Baumber, R; Berger, MS; Eberhard, DA; Haas-Kogan, DA; Jelluma, N; Kapadia, A; Lamborn, KR; Malec, M; Prados, MD; Stokoe, D; Tihan, T | 1 |
| Kurisu, K; Okamura, T | 1 |
| Abrey, LE; Chang, S; Cowell, JK; DeAngelis, LM; Gilbert, MR; Grefe, CN; Holland, EC; Kuhn, JG; Lamborn, K; Lassman, AB; Lieberman, FS; Nowak, NJ; Pao, W; Prados, M; Raizer, JJ; Razier, JR; Rossi, MR; Shih, AH; Wen, P; Wilson, R; Yung, WA | 1 |
| Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D | 1 |
| Berger, MS; Keles, GE | 1 |
| Cheng, CK; Fan, QW; Hackett, CS; Knight, ZA; Nicolaides, TP; Shokat, KM; Weiss, WA | 1 |
| Bertalanffy, A; Dieckmann, K; Dietrich, W; Gelpi, E; Hainfellner, JA; Marosi, C; Prayer, D; Preusser, M; Rottenfusser, A; Widhalm, G | 1 |
4 review(s) available for erlotinib hydrochloride and Glioma
| Article | Year |
|---|---|
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Quinazolines; Temozolomide | 2009 |
Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug Combinations; Drug Synergism; Erlotinib Hydrochloride; Glioma; Humans; Models, Biological; Neoplasm Grading; Quinazolines | 2011 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System Neoplasms; Cetuximab; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Quinazolines; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
15 trial(s) available for erlotinib hydrochloride and Glioma
| Article | Year |
|---|---|
Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Cerebrovascular Circulation; Child; Child, Preschool; Contrast Media; Erlotinib Hydrochloride; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Prognosis; Treatment Failure; Young Adult | 2018 |
Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Disease Progression; Erlotinib Hydrochloride; Glioma; Humans; Magnetic Resonance Imaging; Neuroimaging; Prognosis; Prospective Studies; Radiotherapy Dosage; Regression Analysis; Treatment Failure | 2017 |
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Survival Rate; Tissue Distribution; Young Adult | 2014 |
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Topics: Adolescent; Adult; Anticonvulsants; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2009 |
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult | 2010 |
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tissue Distribution | 2010 |
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate; Tissue Distribution | 2010 |
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
Topics: Adolescent; Adult; Brain Stem Neoplasms; Child; Child, Preschool; Erlotinib Hydrochloride; Female; Glioma; Humans; Infant; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Therapies, Investigational; Tissue Distribution; Treatment Outcome; Young Adult | 2011 |
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Quinazolines; Thiazoles; Tissue Distribution; Young Adult | 2012 |
A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Sirolimus; Survival Rate; Tissue Distribution | 2012 |
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Supratentorial Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2005 |
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Clinical Trials as Topic; Cluster Analysis; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Genome; Glioma; Humans; Lung Neoplasms; Models, Biological; Mutation; Nucleic Acid Hybridization; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Time Factors | 2005 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Temozolomide; Treatment Outcome | 2006 |
Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.
Topics: Adult; Aged; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention | 2008 |
21 other study(ies) available for erlotinib hydrochloride and Glioma
| Article | Year |
|---|---|
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Drug Delivery Systems; Glioma; Neoplasm Invasiveness; Rats; Transplantation, Heterologous | 2013 |
Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transdifferentiation; Datasets as Topic; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Glioma; Homeodomain Proteins; Humans; Male; Mice; Mice, Knockout; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; RNA-Seq; Signal Transduction; Transcription Factors; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2021 |
Multimodal Magnetic Resonance Imaging of Treatment-Induced Changes to Diffuse Infiltrating Pontine Gliomas in Children and Correlation to Patient Progression-Free Survival.
Topics: Adolescent; Antineoplastic Agents; Brain; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Contrast Media; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Sirolimus; Statistics, Nonparametric; Survival Analysis; Time Factors; Tumor Burden | 2017 |
Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging.
Topics: Animals; Antineoplastic Agents; Biomarkers; Blood-Brain Barrier; Brain Neoplasms; Disease Models, Animal; Erlotinib Hydrochloride; Glioma; Heme; Heterografts; Humans; Mice; Molecular Imaging; Neovascularization, Pathologic; Optical Imaging; Permeability; Pharmaceutical Preparations; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2013 |
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
Topics: Animals; Brain Neoplasms; Crizotinib; Cyclin-Dependent Kinase Inhibitor p16; Doxycycline; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Processing, Post-Translational; PTEN Phosphohydrolase; Pyrazoles; Pyridines; Quinazolines; Quinolines; Tumor Cells, Cultured | 2015 |
Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Genomics; Glioma; Humans; Male; Middle Aged; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2016 |
Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro.
Topics: Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytostatic Agents; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Inhibitor of Apoptosis Proteins; Pyrimidines; rac1 GTP-Binding Protein; Signal Transduction; Survivin | 2017 |
Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.
Topics: Aged; Animals; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Microfilament Proteins; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Tensins; Time Factors; Tumor Cells, Cultured | 2009 |
Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature.
Topics: Biological Availability; Brain Neoplasms; Child; Combined Modality Therapy; Cystic Fibrosis; Erlotinib Hydrochloride; Exocrine Pancreatic Insufficiency; Female; Glioma; Humans; Malabsorption Syndromes; Pancrelipase; Protein Kinase Inhibitors; Quinazolines | 2009 |
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Topics: Adolescent; Blotting, Western; Cell Proliferation; Child; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Prognosis; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Deletion; Tumor Cells, Cultured | 2009 |
Interstitial infusion of erlotinib in the rodent brain.
Topics: Animals; Body Weight; Brain; Brain Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Microinjections; Neostriatum; Quinazolines; Rats; Rats, Nude | 2009 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide | 2011 |
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Glioma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Rate; Tumor Cells, Cultured; Young Adult | 2012 |
Occupy EGFR.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Kinetics; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Gene expression changes associated with erlotinib response in glioma cell lines.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cluster Analysis; Cyclin-Dependent Kinase Inhibitor p16; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitor of Apoptosis Proteins; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Survivin; Transcription Factors | 2013 |
EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.
Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium; Calcium Signaling; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Purinergic; Tumor Cells, Cultured | 2004 |
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Patient Selection; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Evolution of management strategies for cerebral gliomas: the effects of science and technology.
Topics: Antibiotics, Antineoplastic; Brain Neoplasms; DNA Repair; DNA-Binding Proteins; Doxorubicin; Endonucleases; Erlotinib Hydrochloride; Gene Silencing; Genes, erbB-1; Genome, Human; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Xeroderma Pigmentosum Group D Protein | 2005 |
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Furans; Glioma; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; PTEN Phosphohydrolase; Pyridines; Pyrimidines; Quinazolines; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Cells, Cultured | 2007 |